DE3262580D1 - Steroid derivatives substituted in the 11-beta position, process for their preparation, their utilization as medicaments and compositions containing them - Google Patents

Steroid derivatives substituted in the 11-beta position, process for their preparation, their utilization as medicaments and compositions containing them

Info

Publication number
DE3262580D1
DE3262580D1 DE8282400025T DE3262580T DE3262580D1 DE 3262580 D1 DE3262580 D1 DE 3262580D1 DE 8282400025 T DE8282400025 T DE 8282400025T DE 3262580 T DE3262580 T DE 3262580T DE 3262580 D1 DE3262580 D1 DE 3262580D1
Authority
DE
Germany
Prior art keywords
medicaments
utilization
preparation
compositions containing
derivatives substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
DE8282400025T
Other languages
English (en)
Inventor
Jean Georges Teutsch
Germain Costerousse
Daniel Philibert
Roger Deraert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
EXELGYN, PARIS, FR
Original Assignee
Roussel Uclaf SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roussel Uclaf SA filed Critical Roussel Uclaf SA
Application granted granted Critical
Publication of DE3262580D1 publication Critical patent/DE3262580D1/de
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C07J41/0016—Oximes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/005—Ketals
    • C07J21/006—Ketals at position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0077—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0077—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom
    • C07J41/0083—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom substituted in position 11-beta by an optionally substituted phenyl group not further condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/001—Oxiranes

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE8282400025T 1981-01-09 1982-01-08 Steroid derivatives substituted in the 11-beta position, process for their preparation, their utilization as medicaments and compositions containing them Expired DE3262580D1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR8100272A FR2497807A1 (fr) 1981-01-09 1981-01-09 Nouveaux derives steroides substitues en 11b, leur proc ede de preparation et leur application comme medicament

Publications (1)

Publication Number Publication Date
DE3262580D1 true DE3262580D1 (en) 1985-04-25

Family

ID=9253984

Family Applications (2)

Application Number Title Priority Date Filing Date
DE8282400025T Expired DE3262580D1 (en) 1981-01-09 1982-01-08 Steroid derivatives substituted in the 11-beta position, process for their preparation, their utilization as medicaments and compositions containing them
DE1999175073 Active DE19975073I2 (de) 1981-01-09 1982-01-08 In Stellung 11-beta substituierte Steroidderivate,Verfahren zu ihrer Herstellung, ihre Anwendung als Arzneimittel und Zusammensetzungen, die sie enthalten.

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE1999175073 Active DE19975073I2 (de) 1981-01-09 1982-01-08 In Stellung 11-beta substituierte Steroidderivate,Verfahren zu ihrer Herstellung, ihre Anwendung als Arzneimittel und Zusammensetzungen, die sie enthalten.

Country Status (22)

Country Link
US (4) US4386085A (de)
EP (1) EP0057115B1 (de)
JP (2) JPS57168000A (de)
KR (1) KR870001936B1 (de)
AU (2) AU550334B2 (de)
BG (1) BG60768B2 (de)
CA (1) CA1193246A (de)
DE (2) DE3262580D1 (de)
DK (1) DK166680B1 (de)
ES (2) ES8305786A1 (de)
FI (1) FI77872C (de)
FR (1) FR2497807A1 (de)
GE (1) GEP19960479B (de)
HU (1) HU185158B (de)
IE (1) IE52595B1 (de)
LT (1) LT2618B (de)
MD (1) MD207C2 (de)
NL (1) NL300001I2 (de)
PT (1) PT74263A (de)
SG (1) SG45987G (de)
SU (1) SU1447289A3 (de)
ZA (1) ZA8231B (de)

Families Citing this family (143)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA8231B (en) * 1981-01-09 1982-11-24 Roussel Uclaf New 11 -substituted steroid derivatives, their preparation, their use as medicaments, the compositions containing them and the new intermediates thus obtained
FR2528434B1 (fr) 1982-06-11 1985-07-19 Roussel Uclaf Nouveaux 19-nor steroides substitues en 11b et eventuellement en 2, leur procede de preparation et leur application comme medicament
US4978657A (en) * 1981-01-09 1990-12-18 Roussel Uclaf Novel 11β-substituted-19-nor-steroids
FR2522328B1 (fr) * 1982-03-01 1986-02-14 Roussel Uclaf Nouveaux produits derives de la structure 3-ceto 4,9 19-nor steroides, leur procede de preparation et leur application comme medicaments
FR2640977A2 (en) * 1982-06-11 1990-06-29 Roussel Uclaf New position-11 substituted 19-norsteroids and their application as medicinal products.
DE3231828A1 (de) * 1982-08-24 1984-03-01 Schering AG, 1000 Berlin und 4709 Bergkamen 17(alpha)-alkinyl-3,3-alkylendioxy-5(alpha),10(alpha)-epoxy-9(11)-estren-17(beta)-ol-derivate, verfahren zu deren herstellung und deren verwendung zur weiterverarbeitung
DE3231827A1 (de) * 1982-08-24 1984-03-01 Schering AG, 1000 Berlin und 4709 Bergkamen 11ss-aryl-17(alpha)-alkinyl-17ss-hydroxy-4,9(10)- estradien-3-on-derivate, deren herstellung und diese enthaltende pharmazeutische praeparate
DE3306121A1 (de) * 1983-02-18 1984-09-06 Schering AG, 1000 Berlin und 4709 Bergkamen 11ss-aryl-spirolaktone in der steroidreihe, verfahren zu deren herstellung und diese verbindungen enthaltende pharmazeutische praeparate
DE3461090D1 (en) * 1983-02-18 1986-12-04 Schering Ag 11-beta-aryl-estradienes, process for their preparation and pharmaceutical compositions containing them
IL68222A (en) * 1983-03-24 1987-02-27 Yeda Res & Dev Contraceptive compositions comprising a progesterone antagonist and a blocker of progesterone activity
DE3320580A1 (de) * 1983-06-03 1984-12-06 Schering AG, 1000 Berlin und 4709 Bergkamen D-homo-4,9,16-estratriene, deren herstellung und diese enthaltende pharmazeutische praeparate
NO162241C (no) * 1983-06-14 1989-11-29 Roussel Uclaf Nye, radioaktive estradienderivater merket med jod125, fremgangsmaate ved deres fremstilling og deres anvendelse vedradioimmunologisk undersoekelse og mengdebestemmelse av steroider i biologiske vaesker.
FR2549067B1 (fr) * 1983-06-14 1985-12-27 Roussel Uclaf Derives estradieniques radioactifs marques au tritium, leur procede de preparation et leur application pour l'etude et le dosage radio-immunologique de steroides dans les fluides biologiques
FR2548192B1 (fr) * 1983-06-20 1985-11-22 Roussel Uclaf Derives estradieniques radioactifs marques a l'iode, leur procede de preparation et leur application aux dosages radioimmunologiques
DE3446661A1 (de) * 1984-12-18 1986-06-19 Schering AG, 1000 Berlin und 4709 Bergkamen Neue 13(alpha)-alkyl-17(beta)-(3-acyloxypropyl)-gonane
ES533260A0 (es) * 1983-06-15 1985-02-01 Schering Ag Procedimiento para la preparacion de 13a-alquilgonanos
IT1212835B (it) * 1983-08-18 1989-11-30 Lehner Ag Derivati di acidi biliari, procedimento per la loro preparazione e relative composizioni farmaceutiche.
DE3337450A1 (de) * 1983-10-12 1985-04-25 Schering AG, 1000 Berlin und 4709 Bergkamen Prostaglandine und antigestagene fuer den schwangerschaftsabbruch
AU572589B2 (en) 1983-12-14 1988-05-12 Upjohn Company, The 11(alpha)-difluoromethyl and (e)-and (z)-11-fluoromethylene steroids
DE3347126A1 (de) * 1983-12-22 1985-07-11 Schering AG, 1000 Berlin und 4709 Bergkamen 11ss-aryl-estradiene, deren herstellung und diese enthaltende pharmazeutische praeparate
FR2566779B2 (fr) * 1984-06-29 1987-03-06 Roussel Uclaf Nouveaux derives steroides substitues en 11b, leur procede de preparation et leur application comme medicaments
US5116830A (en) * 1984-08-17 1992-05-26 Sri International Stereoisomerically pure 17α-ethynyl-estra-2-en-17β-ol and the 17β esters thereof, methods of preparation and uses
DE3438500C1 (de) * 1984-10-18 1986-05-28 Schering AG, 1000 Berlin und 4709 Bergkamen Verfahren zur Herstellung 11ß-substituierter Δ↑9↑-19-Norsteroide
FR2573657B1 (fr) * 1984-11-29 1989-05-12 Roussel Uclaf Produit comprenant une substance antiprogestomimetique et une substance uterotonique
DE3504421A1 (de) * 1985-02-07 1986-08-07 Schering AG, 1000 Berlin und 4709 Bergkamen Neue 11ss-phenyl-gonane, deren herstellung und diese enthaltende pharmazeutische praeparate
AU580843B2 (en) * 1985-02-07 1989-02-02 Schering Aktiengesellschaft 11``-phenyl-gonanes, their manufacture and pharmaceutical preparations containing them
DE3506785A1 (de) * 1985-02-22 1986-08-28 Schering AG, Berlin und Bergkamen, 1000 Berlin 11ss-n,n-dimethylaminophenyl-estradiene, deren herstellung und diese enthaltende pharmazeutische praeparate
GB8513723D0 (en) * 1985-05-31 1985-07-03 Erba Farmitalia 11-beta substituted steroids
DE3531903A1 (de) * 1985-09-05 1987-03-12 Schering Ag Oxytocin und antigestagen zur einleitung der geburt bzw. zum therapeutischen abbruch der graviditaet
DE3533175A1 (de) * 1985-09-13 1987-03-19 Schering Ag Antigestagene zur verschiebung der endometrialen reifung
FR2596395B1 (fr) * 1986-03-26 1989-05-26 Roussel Uclaf Nouveaux steroides comportant un cycle spirannique en position 17, leur procede de preparation, leur application comme medicaments et les compositions les renfermant
FR2598421B1 (fr) * 1986-05-06 1988-08-19 Roussel Uclaf Nouveaux produits 19-nor ou 19-nor d-homo steroides substitues en position 11b par un radical phenyle portant un radical alkynyle, leur procede de preparation, leur application comme medicaments et les compositions les renfermant
DE3761308D1 (de) * 1986-07-23 1990-02-08 Akzo Nv 18-phenylestrane-derivate.
DE3625315A1 (de) * 1986-07-25 1988-01-28 Schering Ag 11ss-(4-isopropenylphenyl)-estra-4,9-diene, deren herstellung und diese enthaltende pharmazeutische praeparate
US4774236A (en) * 1986-09-17 1988-09-27 Research Triangle Institute 17α-(substituted-methyl)-17β-hydroxy/esterified hydroxy steroids and pharmaceutical compositions containing them
US5272140A (en) * 1987-01-23 1993-12-21 Akzo N.V. 11-aryl steroid derivatives
IE60780B1 (en) * 1987-01-23 1994-08-10 Akzo Nv New 11-aryl steroid derivatives
DE3708942A1 (de) * 1987-03-18 1988-09-29 Schering Ag 19,11ss-ueberbrueckte steroide, deren herstellung und diese enthaltende pharmazeutische praeparate
US5446178A (en) * 1987-03-18 1995-08-29 Schering Aktiengesellschaft Process for preparing 19,11β-bridged steroids
DE3866410D1 (de) * 1987-04-24 1992-01-09 Akzo Nv 11-arylestranderivate und 11-arylpregnanderivate.
JPH085909B2 (ja) * 1987-07-24 1996-01-24 協和醗酵工業株式会社 Ｕｃｙ１００３誘導体
FR2618783B1 (fr) * 1987-07-30 1991-02-01 Roussel Uclaf Nouveaux 17-aryle steroides, leurs procedes et des intermediaires de preparation comme medicaments et les compositions pharmaceutiques les renfermant
US5208227A (en) * 1987-08-25 1993-05-04 University Of Southern California Method, compositions, and compounds for modulating brain excitability
US5319115A (en) * 1987-08-25 1994-06-07 Cocensys Inc. Method for making 3α-hydroxy, 3β-substituted-pregnanes
ES2053714T3 (es) * 1987-12-12 1994-08-01 Akzo Nv Proceso para la preparacion de 11-arilesteroides.
BE1004905A4 (fr) * 1987-12-30 1993-02-23 Roussel Uclaf Nouveaux derives 17beta-oh 19-nor steroides substitues en 17alpha, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant.
US4954490A (en) * 1988-06-23 1990-09-04 Research Triangle Institute 11 β-substituted progesterone analogs
DE3822770A1 (de) * 1988-07-01 1990-01-04 Schering Ag 13-alkyl-11ss-phenylgonane
DE3832303A1 (de) * 1988-09-20 1990-04-12 Schering Ag 11ss-phenyl-14ssh-steroide
FR2643638B1 (fr) * 1989-02-24 1991-06-14 Roussel Uclaf Nouveaux 19-nor steroides ayant en position 11beta une chaine carbonee comportant une fonction amide ou carbamate, leur procede de preparation et les intermediaires de ce procede, leur application comme medicaments et les compositions pharmaceutiques les contenant
DE3917274A1 (de) * 1989-05-24 1990-11-29 Schering Ag 9(alpha)-hydroxy-19, 11(beta)-ueberbrueckte steroide, deren herstellung und diese enthaltende pharmazeutische praeparate
DE3921059A1 (de) * 1989-06-23 1991-01-10 Schering Ag 11(beta)-aryl-4-estrene, verfahren zu ihrer herstellung sowie deren verwendung als arzneimittel
US5276023A (en) * 1989-08-08 1994-01-04 Roussel Uclaf 19-nor-steroid esters
FR2651435A1 (fr) * 1989-09-07 1991-03-08 Roussel Uclaf Nouvelle utilisation de composes anti-progestomimetiques.
FR2654337B1 (fr) * 1989-11-15 1994-08-05 Roussel Uclaf Nouvelles microspheres injectables biodegradables procede de preparation et suspensions injectables les renfermant.
FR2659233B1 (fr) * 1990-03-06 1994-01-21 Roussel Uclaf Nouvelle utilisation de composes anti-progestomimetiques chez les animaux d'elevage.
DE4018168A1 (de) * 1990-06-01 1991-12-05 Schering Ag Ausgangsverbindungen fuer die herstellung von 10ss-h-steroiden und ein verfahren zur herstellung dieser ausgangsverbindungen
US5407928A (en) * 1990-08-15 1995-04-18 Schering Aktiengesellschaft 11β-aryl-gona-4,9-dien-3-ones
JPH0464052U (de) * 1990-10-05 1992-06-01
US5439913A (en) 1992-05-12 1995-08-08 Schering Aktiengesellschaft Contraception method using competitive progesterone antagonists and novel compounds useful therein
CA2100514C (en) * 1992-07-29 2005-03-29 Johannes A. M. Hamersma 17-spiromethylene steroids
WO1995017192A1 (en) * 1993-12-22 1995-06-29 The Salk Institute For Biological Studies Methods for reducing multidrug resistance
US5681817A (en) 1994-02-04 1997-10-28 The Medical College Of Hampton Roads Treatment of ovarian estrogen dependent conditions
FR2718354B1 (fr) * 1994-04-08 1996-05-03 Roussel Uclaf Application des composés antiglucocorticoïde pour la préparation de médicaments destinés à la prévention ou au traitement des manifestations liées au syndrome de sevrage des narcotiques et les compositions les renfermant.
DE4415590A1 (de) * 1994-04-28 1995-11-02 Schering Ag Verfahren zur stereoselektiven Einführung einer Alkinylseitenkette an 11ß-Aryl-substituierten 13alpha-Alkylgonan-17-onen
US5780220A (en) * 1994-05-19 1998-07-14 Trustees Of The University Of Pennsylvania Methods and compositions for inhibiting HIV replication
US5639598A (en) * 1994-05-19 1997-06-17 The Trustees Of The University Of Pennsylvania Method and kit for identification of antiviral agents capable of abrogating HIV Vpr-Rip-1 binding interactions
EP0683172B1 (de) * 1994-05-19 1997-08-13 Akzo Nobel N.V. 11,21-Bisphenyl-19-nor-pregnan Derivate
US5521166A (en) * 1994-12-19 1996-05-28 Ortho Pharmaceitical Corporation Antiprogestin cyclophasic hormonal regimen
ZA9510926B (en) 1994-12-23 1996-07-03 Schering Ag Compounds with progesterone-antagonistic and antiestrogenic action to be used together for female contraception
US5929262A (en) * 1995-03-30 1999-07-27 The United States Of America As Represented By The Department Of Health And Human Services Method for preparing 17α-acetoxy-11β-(4-N, N-dimethylaminophyl)-19-Norpregna-4,9-diene-3, 20-dione, intermediates useful in the method, and methods for the preparation of such intermediates
US5767113A (en) * 1995-05-10 1998-06-16 The Salk Institute For Biological Studies Compounds useful for concurrently activating glucocorticoid-induced response and reducing multidrug resistance
IL118974A (en) * 1995-08-17 2001-09-13 Akzo Nobel Nv History 11 - (Transformed Phenyl) - Astra - 4, 9 - Diane, their preparation and pharmaceutical preparations containing them
CA2253673C (en) 1996-05-01 2009-09-08 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services 21-substituted progesterone derivatives as new antiprogestational agents
US6900193B1 (en) 1996-05-01 2005-05-31 The United States Of America As Represented By The Department Of Health And Human Services Structural modification of 19-norprogesterone I: 17-α-substituted-11-β-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents
DE19706061A1 (de) * 1997-02-07 1998-08-13 Schering Ag Antigestagen wirksame Steroide mit fluorierter 17alpha-Alkylkette
DE19745085A1 (de) * 1997-10-11 1999-04-15 Jenapharm Gmbh 11ß-Benzaldoxim-9alpha,10alpha-epoxy-estr-4-en-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Präparate
DE19809845A1 (de) * 1998-03-03 1999-09-09 Jenapharm Gmbh S-substituierte 11beta-Benzaldoxim-estra-4,9-dien-kohlensäurethiolester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zubereitungen
US6020328A (en) * 1998-03-06 2000-02-01 Research Triangle Institute 20-keto-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
ATE317699T1 (de) * 1998-05-15 2006-03-15 Univ Leland Stanford Junior Glucocorticoid receptor antagonisten zur behandlung von demenz
ATE473759T1 (de) 1998-05-22 2010-07-15 Univ Leland Stanford Junior Bifunktionelle moleküle sowie darauf basierende therapien.
US6262042B1 (en) 1998-05-29 2001-07-17 Research Triangle Institute 17β-amino and hydroxylamino-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
US5962444A (en) * 1998-05-29 1999-10-05 Research Triangle Institute 17β-nitro-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
WO1999066915A2 (en) 1998-06-23 1999-12-29 Southern Illinois University At Carbondale Therapeutic applications of estrogenic carboxylic acids
US20020169205A1 (en) * 1998-09-29 2002-11-14 Krzysztof Chwalisz Implantation rates after in vitro fertilization, and treatment of infertility and early pregnancy loss with a nitric oxide donor or substrate alone or in combination with progesterone, and a method for contraception with nitric oxide inhibitors in combination with antiprogestins or other agents
CN1117759C (zh) * 1999-09-02 2003-08-13 上海中西药业股份有限公司 甾体化合物,其制备方法和其药物组合物及其应用
US20030013694A1 (en) * 2001-05-25 2003-01-16 Jens Hoffmann Use and compositions of antiprogestins for treatment of prostate diseases
FR2826004B1 (fr) * 2001-06-13 2008-03-28 Aventis Pharma Sa Procede de preparation de derives estrogenes
EP1285927A3 (de) 2001-08-16 2005-06-29 Schering Aktiengesellschaft Verwendung von Glucocorticoid-Rezeptorantagonisten zur Vorbeugung und Behandlung von Erkrankungen des männlichen Reproduktionssystems
US7326697B2 (en) 2002-04-29 2008-02-05 Corcept Therapeutics, Inc. Methods for increasing the therapeutic response to electroconvulsive therapy
DE10221034A1 (de) 2002-05-03 2003-11-20 Schering Ag 17alpha-Fluoralkyl-11ß-benzaldoxim-Steroide, Verfahren zu deren Herstellung, diese Steroide enthaltende pharmazeutische Präparate sowie deren Verwendung zur Herstellung von Arzneimitteln
US7250408B2 (en) 2002-12-16 2007-07-31 Bayer Schering Pharma Ag Glucocorticoid receptor antagonists for prophylaxis and therapy of glucocorticoid-mediated hypogonadism, of sexual dysfunction and/or infertility
FR2850022B1 (fr) * 2003-01-22 2006-09-08 Centre Nat Rech Scient Nouvelle utilisation de la mifepristone et de ses derives comme modulateurs de la voie de signalisation des proteines hedgehog et ses applications
EP1613640A4 (de) * 2003-02-28 2010-05-19 Us Gov Health & Human Serv Verfahren zur herstellung von 17 alpha-acetoxy-11 beta-(4-n,n-dimethylaminophenyl)-19-norpregna-4,9-dien-3,20-dion, zwischenprodukte dafür, und verfahren zur herstellung dieser zwischenprodukte
CN101014349A (zh) * 2003-06-20 2007-08-08 病毒基因混和公司 抗病毒组合物及其使用方法
CN103259027A (zh) 2005-04-28 2013-08-21 普罗透斯数字保健公司 药物信息系统
US20070105828A1 (en) * 2005-08-19 2007-05-10 Glenmark Pharmaceuticals Limited Novel polymorph form M of mifepristone and process for its preparation
JP2009508494A (ja) 2005-09-16 2009-03-05 ラプトール ファーマシューティカル インコーポレイテッド Ｃｒを含むタンパク質に対して特異的な受容体−結合タンパク質（ｒａｐ）変異体を含む組成物およびその使用
JP4382735B2 (ja) 2005-10-06 2009-12-16 独立行政法人科学技術振興機構 神経因性疼痛治療剤
DE102005059222B4 (de) * 2005-12-08 2007-10-11 Bayer Schering Pharma Ag 11ß-Benzaldoximderivate von D-Homoestra-4,9-dien-3-onen
DK1991559T3 (da) 2006-02-17 2012-10-08 Janssen Pharmaceutica Nv Oxasteroidderivater som selektive progesteronreceptormodulatorer
US20070270393A1 (en) * 2006-02-17 2007-11-22 Theresa Buckley Methods and compositions for modulation of sleep cycle
DE102006018888A1 (de) * 2006-04-18 2007-10-25 Bayer Schering Pharma Ag Verfahren zur Herstellung von 4-[17beta-Methoxy-17alpha-methoxymethyl-3-oxoestra-4,9-dien-11beta-yl]benzaldehyd-(E)-oxims (Asoprisnil)
WO2008039482A2 (en) * 2006-09-26 2008-04-03 The Regents Of The University Of California Methods and compositions for cancer prevention and treatment
US9517240B2 (en) 2006-09-26 2016-12-13 The Regents Of The University Of California Methods and compositions for cancer prevention and treatment
EP3693376A1 (de) 2006-10-24 2020-08-12 Allergan Pharmaceuticals International Limited Zusammensetzungen zur unterdrückung der endometriumproliferation
KR20090105944A (ko) * 2007-01-17 2009-10-07 레프로스 쎄라피우틱스 아이엔씨. 11-(4-아미노페닐)-19-노르프레그나-4,9(10)-디엔-3,20-디온 유도체의 약학적으로 허용가능한 염
HU228636B1 (en) * 2007-06-27 2013-04-29 Richter Gedeon Nyrt Industrial method for the synthesis of 17-acetoxy-11betha-4[-(dimethylamino)-phenyl]-21-methoxy-19-norpregna-4,9-dien-3,20-dione and the key intermediates of the process
TWI539953B (zh) 2008-04-28 2016-07-01 瑞波若斯治療學公司 用於治療乳癌之組成物和方法
PT2398500T (pt) 2009-02-20 2019-06-14 2 Bbb Medicines B V Sistema de entrega de medicamentos à base de glutationas
TWI556839B (zh) 2009-05-06 2016-11-11 研究室護膚股份有限公司 包含活性劑－磷酸鈣粒子複合物之皮膚遞送組成物及其使用方法
DE102009034366A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-methylenoxyalkylenaryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034362A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034367A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-benzyliden-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102009034368A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-acyloxyalkylenphenyl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034526A1 (de) 2009-07-21 2011-02-10 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-ethinylphenyl-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102009034525A1 (de) 2009-07-21 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102010007722A1 (de) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten
DE102010007719A1 (de) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten
EP2550288A1 (de) 2010-03-22 2013-01-30 Repros Therapeutics Inc. Zusammensetzungen und verfahren zur nichttoxischen freisetzung von antiprogestinen
US11103514B2 (en) 2010-05-26 2021-08-31 Corcept Therapeutics, Inc. Treatment of muscular dystrophy
DE102011004899A1 (de) 2011-03-01 2012-09-06 Bayer Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
US20130029953A1 (en) * 2011-07-28 2013-01-31 Klaus Nickisch Progesterone antagonists
EP2868320A1 (de) 2013-11-03 2015-05-06 Flamina Holding AG Zusammensetzung oder Gruppe von Zusammensetzungen zur Behandlung von menschlichen Zellen
JP6821582B2 (ja) 2015-03-02 2021-01-27 コーセプト セラピューティクス， インコーポレイテッド Ａｃｔｈ分泌腫瘍を処置するための糖質コルチコイドレセプターアンタゴニストおよびソマトスタチンアナログの使用
EP3277281B1 (de) 2015-03-30 2022-01-05 Corcept Therapeutics, Inc. Verwendung von glukokortikoid-rezeptorantagonisten in kombination mit glukokortikoiden zur behandlung von nebenniereninsuffizienz
CN113797210A (zh) 2015-05-18 2021-12-17 拜耳医药股份有限公司 选择性孕酮受体调节剂(sprm)方案
WO2017027851A1 (en) 2015-08-13 2017-02-16 Corcept Therapeutics, Inc. Method for differentially diagnosing acth-dependent cushing's syndrome
US11110103B2 (en) 2015-12-23 2021-09-07 Oric Pharmaceuticals, Inc. Inhibitors of glucocorticoid receptor
JP6995757B2 (ja) 2015-12-23 2022-01-17 オリック ファーマシューティカルズ，インク． グルココルチコイド受容体の阻害剤
CN108699102A (zh) * 2015-12-23 2018-10-23 欧瑞克制药公司 糖皮质激素受体抑制剂
WO2017127448A1 (en) 2016-01-19 2017-07-27 Corcept Therapeutics, Inc. Differential diagnosis of ectopic cushing's syndrome
EP3214092A1 (de) 2016-03-04 2017-09-06 Bayer Pharma Aktiengesellschaft Prodrugs vom selektiven progesteronrezeptormodulator (sprm) (11.beta.,17.beta.)-17-hydroxy-11-[4-(methylsulphonyl)phenyl]-17-(pentafluoroethyl)estra-4,9-dien-3-on
EP3523315B1 (de) * 2016-10-07 2021-03-24 Oric Pharmaceuticals, Inc. Inhibitor des glucocorticoidrezeptors
CN110099688A (zh) * 2016-11-17 2019-08-06 赛途公司 骨骼肌肥大诱导物
AU2018244928B2 (en) 2017-03-31 2023-10-19 Corcept Therapeutics, Inc. Glucocorticoid receptor modulators to treat cervical cancer
US11213526B2 (en) 2017-06-20 2022-01-04 Corcept Therapeutics, Inc. Methods of treating neuroepithelial tumors using selective glucocorticoid receptor modulators
CN108070016B (zh) * 2017-12-29 2020-07-07 广西万德药业有限公司 甾体环氧异构体的循环利用方法
AU2020367769B2 (en) 2019-10-16 2023-10-12 Corcept Therapeutics Incorporated Method of normalizing the neutrophil to lymphocyte ratio in cancer patients with a selective glucocorticoid receptor antagonist
US20230358768A1 (en) 2019-12-21 2023-11-09 Corcept Therapeutics Incorporated Treatment of, and differential diagnosis between, acth-dependent cushing's syndrome and acth-independent cushing's syndrome
EP4263807A2 (de) 2020-12-18 2023-10-25 Instil Bio (Uk) Limited Verarbeitung von tumorinfiltrierenden lymphozyten
KR20220149828A (ko) 2021-04-30 2022-11-09 삼성전자주식회사 반도체 소자
WO2023000135A1 (en) * 2021-07-19 2023-01-26 Context Biopharma Inc. Processes of making onapristone and intermediates thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3190796A (en) * 1963-04-25 1965-06-22 Upjohn Co Process for inhibiting the growth of micrococcus agilis with 11beta-hydroxy-11-(2-pyridylmethyl)-pregnane-3, 20-dione
FR2377417A1 (fr) * 1977-01-13 1978-08-11 Roussel Uclaf Nouveaux derives steroides substitues en 11b, ainsi que leur procede de preparation
FR2377418A1 (fr) * 1977-01-13 1978-08-11 Roussel Uclaf Nouveaux derives steroides 4,9-dieniques 11b-substitues, leur procede de preparation et leur application comme medicaments
US4197296A (en) * 1977-03-23 1980-04-08 Glaxo Group Limited Androstanes
ZA8231B (en) * 1981-01-09 1982-11-24 Roussel Uclaf New 11 -substituted steroid derivatives, their preparation, their use as medicaments, the compositions containing them and the new intermediates thus obtained

Also Published As

Publication number Publication date
DE19975073I2 (de) 2004-01-08
CA1193246A (fr) 1985-09-10
FI820042L (fi) 1982-07-10
US4634695A (en) 1987-01-06
AU550334B2 (en) 1986-03-20
PT74263A (fr) 1982-02-01
ES517764A0 (es) 1983-12-01
EP0057115A3 (en) 1982-09-29
JPH0466879B2 (de) 1992-10-26
HU185158B (en) 1984-12-28
FI77872B (fi) 1989-01-31
KR840000581A (ko) 1984-02-25
NL300001I2 (nl) 2000-08-01
FI77872C (fi) 1989-05-10
US4519946A (en) 1985-05-28
MD207B1 (ro) 1995-05-31
JPH0234958B2 (de) 1990-08-07
US4447424A (en) 1984-05-08
AU7929682A (en) 1982-07-15
AU579211B2 (en) 1988-11-17
EP0057115A2 (de) 1982-08-04
DE19975073I1 (de) 2000-03-09
US4386085A (en) 1983-05-31
BG60768B2 (bg) 1996-02-29
DK166680B1 (da) 1993-06-28
EP0057115B1 (de) 1985-03-20
AU5123685A (en) 1986-04-17
ES508588A0 (es) 1983-04-16
NL300001I1 (nl) 2000-04-03
ZA8231B (en) 1982-11-24
JPH01279897A (ja) 1989-11-10
LT2618B (lt) 1994-04-25
MD207C2 (ro) 1995-12-31
FR2497807A1 (fr) 1982-07-16
KR870001936B1 (ko) 1987-10-22
SU1447289A3 (ru) 1988-12-23
GEP19960479B (en) 1996-07-22
ES8401498A1 (es) 1983-12-01
FR2497807B1 (de) 1983-07-29
IE820044L (en) 1982-07-09
DK4082A (da) 1982-07-10
IE52595B1 (en) 1987-12-23
ES8305786A1 (es) 1983-04-16
JPS57168000A (en) 1982-10-16
SG45987G (en) 1987-11-13

Similar Documents

Publication Publication Date Title
DE3262580D1 (en) Steroid derivatives substituted in the 11-beta position, process for their preparation, their utilization as medicaments and compositions containing them
IL62082A0 (en) -lactam derivatives,process for the preparation thereof and pharmaceutical compositions containing them
DE3263633D1 (en) Imidazodiazepines, process for their preparation and pharmaceutical compositions containing them
IL57020A (en) Carbazolyl-(4)-oxypropanolamine derivatives,processes for the preparation thereof and pharmaceutical compositions containing the same
PH21386A (en) Platinum-diamine complexes, their pharmaceutical compositions and process for the preparation thereof
DE2960954D1 (en) 1-aryloxy-3-nitratoalkylamino-2-propanols, process for their preparation and pharmaceutical compositions
DE2964209D1 (en) Spiro-furanohydantoin derivatives, process for their preparation and pharmaceutical compositions containing them
IL73888A (en) Ortho-condensed pyrrole derivatives,process for the preparation thereof and pharmaceutical compositions comprising the same
DE2966413D1 (en) Pyrimidinone derivatives, processes for preparing them and pharmaceutical compositions containing them
ZA818867B (en) Pyrazoloindazole derivatives,process for preparing the same,and pharmaceutical compositions containing the same
ZA792042B (en) Substituted 8-hydroxy-1-phenyl-2,3,4,5-tetrahydro-1h-3-benzazepines,process for the preparation thereof and pharmaceutical compositions containing them
ZA834728B (en) Trans-delta 2-prostaglandin d derivatives,process for their preparation and compositions containing them
ZA793682B (en) New piperidylbenzimidazolinone derivatives,processes for their preparation and pharmaceutical compositions containing them
IL62747A (en) 2-guanidinothiazole derivatives,process for the preparation thereof and pharmaceutical compositions comprising the same
IL67403A0 (en) Azolyl-pentene derivatives,process for their preparation and biocidal compositions containing the same
IL56531A (en) Purine derivatives,processes for the preparation thereof and pharmaceutical compositions containing the same
IL56075A (en) Tautomeric 1-cycloalkenoyl-2-anilino-imidazoline derivatives,their preparation and pharmaceutical compositions containing them
DE2966735D1 (en) Quinoxaline-di-n-oxide derivatives, process for their preparation, compositions containing them and their use
ZA824644B (en) Nitrosourea derivatives, process for preparing the same and pharmaceutical composition containing the same
IL73586A0 (en) Pyrimidoisoquinoline derivatives,processes for the preparation thereof and pharmaceutical compositions containing the same
IL64449A0 (en) Imidazole derivatives,a process for the preparation thereof and pharmaceutical compositions containing them
DE3271206D1 (en) Inter-m-phenylene-pgi2 derivatives, process for their preparation and pharmaceutical compositions containing them
IL66913A0 (en) N-phenyl-thiolanine derivatives,process for their preparation and fungicidal compositions containing them
PH15051A (en) Pyrimidine derivative,process for the preparation and compositions containing same
ZA826024B (en) Carbapenem derivatives,their preparation and compositions containing them

Legal Events

Date Code Title Description
V448 Application of spc

Free format text: PRODUCT NAME: MIFEGYNE; REGISTRATION NO/DATE: 46038.00.00, 19990819

Spc suppl protection certif: 199 75 073

Filing date: 19991222

8327 Change in the person/name/address of the patent owner

Owner name: EXELGYN, PARIS, FR

V457 Spc granted

Free format text: PRODUCT NAME: MIFEGYNE; REGISTRATION NO/DATE: 46038.00.00, 19990819

Spc suppl protection certif: 199 75 073

Filing date: 19991222

V464 Spc expired

Free format text: PRODUCT NAME: MIFEGYNE; REGISTRATION NO/DATE: 46038.00.00, 19990819

Spc suppl protection certif: 199 75 073

Filing date: 19991222